Skip to main content
OpenTrials

Clinical trial condition

Parkinson Disease 4, Autosomal Dominant Lewy Body

Explore clinical trials studying Parkinson Disease 4, Autosomal Dominant Lewy Body. Study availability and eligibility vary by location and protocol.

226 public trials 33 recruiting studies
Refine in advanced search Browse all conditions

Parkinson Disease 4, Autosomal Dominant Lewy Body trial results

Recruiting

Substudy 06D: Combination Therapies in Second Line (2L) Gastroesophageal Adenocarcinoma (MK-3475-06D/Keymaker-U06)

NCT06445972

Conditions
Digestive System Diseases, Digestive System Neoplasms, Esophageal Cancer, +10 more
Locations
  • University of Arizona Cancer Center-University of Arizona Cancer Center ( Site 8927) Tucson, Arizona, United States
  • UCLA Hematology/Oncology - Santa Monica ( Site 8905) Los Angeles, California, United States
  • Norton Cancer Institute - Downtown ( Site 8900) Louisville, Kentucky, United States
  • The Cancer and Hematology Centers ( Site 8912) Grand Rapids, Michigan, United States
View all 47 locations
View Trial Details
Recruiting

Clinical Trial Evaluating the Safety, Tolerability and Preliminary Efficacy of BNT116 Alone and in Combinations in Patients With Advanced Non-small Cell Lung Cancer

NCT05142189

Conditions
Bronchial Neoplasms, Carcinoma, Bronchogenic, Carcinoma, Non-Small-Cell Lung, +19 more
Locations
  • University of Kentucky Chandler Medical Center Lexington, Kentucky, United States
  • Norton Cancer Institute Louisville, Kentucky, United States
  • Johns Hopkins Sidney Kimmel Comprehensive Cancer Center Baltimore, Maryland, United States
  • Ohio State University Columbus, Ohio, United States
View all 45 locations
View Trial Details
Recruiting

A Study to Investigate the Pharmacokinetics and Safety of Subcutaneous Rilvegostomig in Adult Participants With Advanced Solid Tumors Previously Treated With Standard of Care Therapy

NCT07161414

Conditions
Advanced Solid Tumors, Parkinson Disease 4, Autosomal Dominant Lewy Body
Locations
  • Research Site Huntersville, North Carolina, United States
  • Research Site San Antonio, Texas, United States
  • Research Site Fairfax, Virginia, United States
  • Research Site Seoul, South Korea
View Trial Details
Recruiting

A Study of Investigational Agents in Participants With Previously Treated Stage IV Nonsquamous Non-small Cell Lung Cancer (NSCLC) (MK-3475-01H/KEYMAKER-U01)

NCT06780085

Conditions
Bronchial Neoplasms, Carcinoma, Bronchogenic, Carcinoma, Non-Small-Cell Lung, +8 more
Locations
  • University of Kentucky Chandler Medical Center ( Site 0019) Lexington, Kentucky, United States
  • MedStar Franklin Square Medical Center ( Site 0033) Baltimore, Maryland, United States
  • AHN Cancer Institute - Allegheny General ( Site 9501) Pittsburgh, Pennsylvania, United States
  • Centro de Estudios Clínicos SAGA ( Site 0161) Santiago, Region M. de Santiago, Chile
View all 34 locations
View Trial Details
Recruiting

A Clinical Study of Intismeran Autogene (V940) and Pembrolizumab (MK-3475) in People With Melanoma (V940-012/INTerpath-012)

NCT06961006

Conditions
Malignant Melanoma, Melanoma, Neoplasms, +11 more
Locations
  • Highlands Oncology Group ( Site 4042) Springdale, Arkansas, United States
  • UCSF Medical Center at Mission Bay ( Site 4044) San Francisco, California, United States
  • John Theurer Cancer Center at Hackensack University Medical Center ( Site 4047) Hackensack, New Jersey, United States
  • Inova Schar Cancer Institute ( Site 4046) Fairfax, Virginia, United States
View all 38 locations
View Trial Details
Recruiting

Pembrolizumab (MK-3475) Plus Investigational Agents in Resectable Non-small Cell Lung Cancer (NSCLC) (MK-3475-01E/KEYMAKER-U01)

NCT06788912

Conditions
Lung Diseases, Lung Neoplasm Malignant, Lung Neoplasms, +6 more
Locations
  • Southern Cancer Center (SCC) ( Site 8004) Daphne, Alabama, United States
  • Sansum Clinic (Ridley Tree) ( Site 8012) Santa Barbara, California, United States
  • Rocky Mountain Cancer Centers (RMCC) ( Site 8011) Lone Tree, Colorado, United States
  • MedStar Franklin Square Medical Center ( Site 0033) Baltimore, Maryland, United States
View all 38 locations
View Trial Details
Recruiting

A Study to Evaluate Investigational Agents With or Without Pembrolizumab (MK-3475) in Participants With Advanced Esophageal Cancer Previously Exposed to Programmed Cell Death 1 Protein (PD-1)/ Programmed Cell Death Ligand 1 (PD-L1) Treatment (MK-3475-06B)

NCT05319730

Conditions
Carcinoma, Carcinoma, Squamous Cell, Digestive System Diseases, +13 more
Locations
  • University of Arizona Cancer Center-University of Arizona Cancer Center ( Site 4927) Tucson, Arizona, United States
  • UCLA Hematology/Oncology - Santa Monica ( Site 4905) Los Angeles, California, United States
  • Hematology-Oncology Associates of Central NY, P.C. ( Site 4925) East Syracuse, New York, United States
  • Columbia University Irving Medical Center-CUIMC Herbert Irving Comprehensive Cancer Center Clinical ( Site 4907) New York, United States
View all 59 locations
View Trial Details
Recruiting

A Study of Calderasib (MK-1084) Plus Pembrolizumab (MK-3475) in Participants With KRAS G12C Mutant Non-small Cell Lung Cancer (NSCLC) With Programmed Cell Death Ligand 1 (PD-L1) Tumor Proportion Score (TPS) ≥50% (MK-1084-004/KANDLELIT-004)

NCT06345729

Conditions
Bronchial Neoplasms, Carcinoma, Bronchogenic, Carcinoma, Non-Small-Cell Lung, +9 more
Locations
  • CBCC Global Research, Inc. ( Site 0123) Bakersfield, California, United States
  • Beverly Hills Cancer Center ( Site 0116) Beverly Hills, California, United States
  • Stamford Hospital ( Site 0136) Stamford, Connecticut, United States
  • Mount Sinai Cancer Center ( Site 0137) Miami Beach, Florida, United States
View all 225 locations
View Trial Details
Recruiting

A First-in-human, Dose Escalation and Indication Expansion Study of BNT3212 as Monotherapy or in Combination With BNT327 in Adults With Advanced Solid Tumors

NCT07147348

Conditions
Advanced Solid Tumor, Parkinson Disease 4, Autosomal Dominant Lewy Body
Locations
  • Cancer Research SA Adelaide, Australia
  • Monash Medical Centre Clayton, Australia
  • Peter MacCallum Cancer Centre Melbourne, Australia
  • The Alfred Hospital Melbourne, Australia
View all 17 locations
View Trial Details

Related conditions